6533b833fe1ef96bd129c24c
RESEARCH PRODUCT
ESH position paper: renal denervation - an interventional therapy of resistant hypertension
Giuseppe ManciaCostas TsioufisGuido GrassiSverre E. KjeldsenPhilippe Van De BorneLuis M. RuilopeRoland E. SchmiederKrzysztof NarkiewiczRedon JosepGianfranco Paratisubject
medicine.medical_specialtySympathetic nervous systemSympathetic Nervous SystemSystolePhysiologyCentral nervous systemCardiologyKidneyNeurosurgical ProceduresRenal ArteryDiastoleInternal medicineInternal MedicinemedicineHumansSystoleIntensive care medicineSocieties MedicalAgedRandomized Controlled Trials as TopicDenervationKidneybusiness.industryresistant hypertensionMiddle AgedDenervationEuropeTreatment OutcomeBlood pressuremedicine.anatomical_structureHypertensionCatheter AblationCardiologyPosition paperRenal denervationCardiology and Cardiovascular MedicinebusinessSensory nervedescription
Experts from the European Society of Hypertension prepared this position paper in order to summarize current evidence, unmet needs and practical recommendations on the application of percutaneous transluminal ablation of renal nerves [renal denervation (RDN)] as a novel therapeutic strategy for the treatment of resistant hypertension. The sympathetic nervous activation to the kidney and the sensory afferent signals to the central nervous system represent the targets of RND. Clinical studies have documented that catheter-based RDN decreases both efferent sympathetic and afferent sensory nerve traffic leading to clinically meaningful systolic and diastolic blood pressure (BP) reductions in patients with resistant hypertension. This position statement intends to facilitate a better understanding of the effectiveness, safety, limitations and issues still to be addressed with RDN.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-04-04 |